Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2013

Primary Completion Date

October 26, 2022

Study Completion Date

October 26, 2022

Conditions

Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic SyndromeSecondary Myelodysplastic Syndrome

Interventions

DRUG

Azacitidine (AZC)

Given IV or SC

DRUG

Decitabine

Given IV or SC

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (4)

Cleveland Clinic Foundation, Cleveland

Mayo Clinic in Arizona, Scottsdale

Fred Hutch/University of Washington Cancer Consortium, Seattle

Kaiser Permanente Washington, Seattle

All Listed Sponsors

lead

Fred Hutchinson Cancer Center

OTHER

NCT01812252 - Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter